Funding in, findings out
For any dataset: the NCI award that paid to create it, and the awards that got a published finding out of it afterwards.
MMRF-COMMPASS
Multiple Myeloma CoMMpass Study
0 awards paid to create it · 17 awards funded work that used it
1. Awards that paid to create this data
2. The dataset
3. Articles that used it (6 of 9)
- Schmidt et al. · Blood cancer journal · 2019145 citations
- Rustad et al. · Nature communications · 2020143 citations
- Barwick et al. · Nature communications · 2019131 citations
- Oben et al. · Nature communications · 2021126 citations
- Maura et al. · Journal of clinical oncology : official journal of the American Society of Clinical Oncology · 2024117 citations
- Lazzari et al. · Nature communications · 2017106 citations
The best connected are shown.
4. Awards those articles were funded by (6 of 17)
- Overcoming IMiD resistance in Myeloma · Craig C. Hofmeister, Mitch A Phelps · FY2016–2020funded 2 of these 9 articles
- Project 1: Developing MRD-based therapeutic strategy in newly diagnosed multipl… · Jill Corre, Nikhil C. Munshi · FY2011–2026funded 1 of these 9 articles
- SPORE in Multiple Myeloma · KENNETH C. ANDERSON, Nikhil C. Munshi · FY2003–2023funded 1 of these 9 articles
- Winship Cancer Institute Cancer Center Support Grant · Suresh S Ramalingam, Lawrence H. Boise · FY2009–2026funded 3 of these 9 articles
- Cancer Research Training and Education Coordination · Kerry L Burnstein, David Benner Lombard · FY2019–2026funded 2 of these 9 articles
- Cancer Center Administration · ALEX MACDONALD, SELWYN M VICKERS · FY1985–2026funded 5 of these 9 articles
The best connected are shown.
Why one side of this chain is empty
- No repository or reviewer names this dataset's marker paper, so no award can be credited with creating it.
Awards that funded work using this data
9 of 10 traced articles report an NCI award.
| Award | Project | Articles it is credited on | Evidence |
|---|---|---|---|
| R01CA201382 R01FY2016–2020$2.6M | Overcoming IMiD resistance in Myeloma | API | |
| P01CA155258 P01FY2011–2026$60.2M | Project 1: Developing MRD-based therapeutic strategy in newly diagnosed multiple myeloma | API | |
| P50CA100707 P50FY2003–2023$78.9M | SPORE in Multiple Myeloma | API | |
| R35CA197603 R35FY2016–2022$5.8M | HARNESSING HOST RESPONSE TO PREVENT MYELOMA | API | |
| P30CA138292 P30FY2009–2026$85.7M | Winship Cancer Institute Cancer Center Support Grant | API | |
| R01CA192844 R01FY2016–2020$1.9M | The Role of CD86 in Multiple Myeloma | API | |
| P30CA240139 P30FY2019–2026$40.9M | Cancer Research Training and Education Coordination | API | |
| K12CA226330 K12FY2018–2026$5.1M | UM Calabresi Clinical Oncology Research Career Development Award | API | |
| P30CA016087 P30FY1985–2026$175.2M | Cancer Center Administration | API | |
| P30CA076292 P30FY1998–2026$166.7M | Immuno-Oncology | API | |
| P50CA186781 P50FY2015–2025$43.6M | Developmental Research Program | API | |
| P30CA008748 P30FY1985–2026$718.0M | Cancer Center Administration | API | |
| P30CA023100 P30FY1985–2026$246.3M | Solid Tumor Therapeutics Program | API | |
| R01CA183968 R01FY2014–2018$2.3M | The Role of Cereblon Pathways in Myeloma | API | |
| R01CA205944 R01FY2017–2021$1.8M | Characterization of the Role of ADAR1 in Oncogenic Transformation of Progenitors | API | |
| R21CA189705 R21FY2015–2016$371k | Identifying microRNA Targets for Early Detection of Myeloproliferative Neoplasms | API | |
| R21CA194679 R21FY2015–2016$366k | (PQC2) Niche-responsive RNA editing by ADAR1 in dormant multiple myeloma initiating cell maintenance | API |
Awards that maintain or redistribute this data
Resource and center grants credited on articles that used the data. Kept out of the flow above because they pay for the pipes, not for a cohort or a finding.
| Award | Project | Evidence |
|---|---|---|
| P01CA155258 P01FY2011–2026$60.2M | Project 1: Developing MRD-based therapeutic strategy in newly diagnosed multiple myeloma | API |
| P30CA008748 P30FY1985–2026$718.0M | Cancer Center Administration | API |
| P30CA016087 P30FY1985–2026$175.2M | Cancer Center Administration | API |
| P30CA023100 P30FY1985–2026$246.3M | Solid Tumor Therapeutics Program | API |
| P30CA076292 P30FY1998–2026$166.7M | Immuno-Oncology | API |
| P30CA138292 P30FY2009–2026$85.7M | Winship Cancer Institute Cancer Center Support Grant | API |
| P30CA240139 P30FY2019–2026$40.9M | Cancer Research Training and Education Coordination | API |
| P50CA100707 P50FY2003–2023$78.9M | SPORE in Multiple Myeloma | API |
| P50CA186781 P50FY2015–2025$43.6M | Developmental Research Program | API |
Where the links come from
NIH RePORTER maps a PMID to the awards that reported it. On a dataset’s marker paper that gives the awards which created it; on an article that used the data, the awards which funded that use.
The two sides are not measured alike. Generation is complete: a dataset has one marker paper and every award on it is resolved. Reuse is a sample - the articles using a dataset can number in the thousands, and only the few dozen strongest are retrieved and looked up. Every award shown here funded reuse; there are more that are not shown.
How far it reaches
283 datasets have an award credited with creating them, 80 with using them, and 31 both.
What is missing
No citable accession means no traceable articles; no authoritative marker paper means no attributable generation award. Absence is a gap in the record. Methods.
Start from an award instead, and see every dataset it touches.